ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
ReShape Lifesciences (Nasdaq: RSLS) announced a partial adjournment of its Special Meeting of Stockholders specifically for two critical proposals. The meeting will reconvene on August 7, 2025 to vote on Proposal 2 (Asset Sale Proposal) and Proposal 3 (Charter Amendment Proposal).
The Asset Sale Proposal involves the sale of substantially all ReShape's assets to Ninjour Health International Limited, while the Charter Amendment Proposal relates to amendments needed for the proposed merger with Vyome Therapeutics. Both proposals are essential conditions for completing the merger. All other merger-related proposals were successfully approved by stockholders.
The company urges all stockholders of record as of June 9, 2025 to vote in favor of these proposals, emphasizing their importance for maximizing stockholder value through the merger completion.
ReShape Lifesciences (Nasdaq: RSLS) ha annunciato una sospensione parziale della sua Assemblea Straordinaria degli Azionisti, riguardante specificamente due proposte fondamentali. L'assemblea si riunirà nuovamente il 7 agosto 2025 per votare la Proposta 2 (Proposta di Vendita degli Asset) e la Proposta 3 (Proposta di Modifica dello Statuto).
La Proposta di Vendita degli Asset riguarda la cessione di quasi tutti gli asset di ReShape a Ninjour Health International Limited, mentre la Proposta di Modifica dello Statuto si riferisce alle modifiche necessarie per la fusione proposta con Vyome Therapeutics. Entrambe le proposte sono condizioni essenziali per il completamento della fusione. Tutte le altre proposte correlate alla fusione sono state approvate con successo dagli azionisti.
L'azienda invita tutti gli azionisti registrati al 9 giugno 2025 a votare a favore di queste proposte, sottolineandone l'importanza per massimizzare il valore per gli azionisti attraverso il completamento della fusione.
ReShape Lifesciences (Nasdaq: RSLS) anunció un aplazamiento parcial de su Junta Especial de Accionistas, específicamente para dos propuestas críticas. La reunión se reanudará el 7 de agosto de 2025 para votar la Propuesta 2 (Propuesta de Venta de Activos) y la Propuesta 3 (Propuesta de Enmienda del Estatuto).
La Propuesta de Venta de Activos implica la venta de casi todos los activos de ReShape a Ninjour Health International Limited, mientras que la Propuesta de Enmienda del Estatuto se relaciona con las modificaciones necesarias para la fusión propuesta con Vyome Therapeutics. Ambas propuestas son condiciones esenciales para completar la fusión. Todas las demás propuestas relacionadas con la fusión fueron aprobadas con éxito por los accionistas.
La compañía insta a todos los accionistas registrados al 9 de junio de 2025 a votar a favor de estas propuestas, enfatizando su importancia para maximizar el valor para los accionistas mediante la finalización de la fusión.
ReShape Lifesciences (나스닥: RSLS)는 두 가지 중요한 안건에 대해 주주 특별총회의 일부 연기를 발표했습니다. 총회는 2025년 8월 7일에 재개되어 제안 2(자산 매각 제안)와 제안 3(정관 수정 제안)에 대해 투표할 예정입니다.
자산 매각 제안은 ReShape의 거의 모든 자산을 Ninjour Health International Limited에 매각하는 내용을 포함하며, 정관 수정 제안은 Vyome Therapeutics와의 예정된 합병을 위해 필요한 수정 사항과 관련이 있습니다. 두 제안 모두 합병 완료를 위한 필수 조건입니다. 그 밖의 합병 관련 제안들은 주주들에 의해 성공적으로 승인되었습니다.
회사는 2025년 6월 9일 기준 등록된 모든 주주들에게 이 제안들에 찬성 투표할 것을 촉구하며, 합병 완료를 통해 주주 가치를 극대화하는 데 이 제안들이 중요함을 강조하고 있습니다.
ReShape Lifesciences (Nasdaq : RSLS) a annoncé un ajournement partiel de son Assemblée Générale Extraordinaire des actionnaires, spécifiquement pour deux propositions cruciales. La réunion reprendra le 7 août 2025 afin de voter sur la Proposition 2 (Proposition de Vente d’Actifs) et la Proposition 3 (Proposition de Modification des Statuts).
La Proposition de Vente d’Actifs concerne la cession de la quasi-totalité des actifs de ReShape à Ninjour Health International Limited, tandis que la Proposition de Modification des Statuts porte sur les amendements nécessaires à la fusion proposée avec Vyome Therapeutics. Ces deux propositions sont des conditions essentielles à la réalisation de la fusion. Toutes les autres propositions liées à la fusion ont été approuvées avec succès par les actionnaires.
La société invite tous les actionnaires inscrits au 9 juin 2025 à voter en faveur de ces propositions, soulignant leur importance pour maximiser la valeur actionnariale grâce à la finalisation de la fusion.
ReShape Lifesciences (Nasdaq: RSLS) hat eine teilweise Vertagung seiner Sonderaktionärsversammlung für zwei wichtige Vorschläge angekündigt. Die Versammlung wird am 7. August 2025 wieder aufgenommen, um über Vorschlag 2 (Vermögensverkauf) und Vorschlag 3 (Satzungsänderung) abzustimmen.
Der Vorschlag zum Vermögensverkauf beinhaltet den Verkauf nahezu aller Vermögenswerte von ReShape an Ninjour Health International Limited, während sich der Vorschlag zur Satzungsänderung auf die für die geplante Fusion mit Vyome Therapeutics erforderlichen Änderungen bezieht. Beide Vorschläge sind wesentliche Voraussetzungen für den Abschluss der Fusion. Alle anderen fusionbezogenen Vorschläge wurden von den Aktionären erfolgreich genehmigt.
Das Unternehmen fordert alle am 9. Juni 2025 eingetragenen Aktionäre auf, diesen Vorschlägen zuzustimmen und betont deren Bedeutung zur Maximierung des Aktionärswerts durch den Abschluss der Fusion.
- All other merger-related proposals have been successfully approved by stockholders
- Management believes the merger will maximize value for stockholders
- Insufficient stockholder support for critical Asset Sale and Charter Amendment proposals
- Delay in merger completion due to proposal adjournment
- Risk of merger failure if proposals are not approved
Insights
ReShape's merger with Vyome hinges on pending stockholder approval for asset sale and charter amendment proposals.
ReShape Lifesciences is navigating a complex corporate restructuring that has reached a critical juncture. The company has secured stockholder approval for several merger-related proposals but still needs approval for two crucial conditions to complete its merger with Vyome Therapeutics: the Asset Sale Proposal and the Charter Amendment Proposal.
The Asset Sale Proposal involves selling substantially all of ReShape's assets to Ninjour Health International Limited (an affiliate of Biorad Medisys). This represents a fundamental transformation of ReShape's business model and operational structure. The Charter Amendment Proposal would modify ReShape's certificate of incorporation to accommodate the proposed merger structure.
Management has taken the significant step of partially adjourning the Special Meeting until August 7, 2025, specifically to allow more time to secure these approvals. CEO Paul Hickey's statement that the merger will "maximize value for stockholders" suggests the current leadership believes this transaction offers better returns than continuing operations under the status quo.
This situation represents a pivotal moment for ReShape Lifesciences. The adjournment indicates the company hasn't yet secured sufficient stockholder support for these transformative measures. The unusual step of asking stockholders who voted against the proposals to reconsider signals management's concern about securing approval and the potential collapse of the merger agreement if these conditions aren't met.
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved
Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or +1-412-232-3651 (from other countries)
IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it conducted a Special Meeting of Stockholders and partially adjourned the meeting for Proposal 2, the proposal to approve the sale of substantially all of ReShape’s assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd. (Asset Sale Proposal), and Proposal 3, the proposal to approve and adopt proposed amendments to ReShape’s certificate of incorporation in connection with ReShape’s proposed merger (Merger) with Vyome Therapeutics, Inc. (Charter Amendment Proposal). All other proposals required for the Merger were approved by stockholders.
ReShape adjourned the Special Meeting of Stockholders with respect to the Asset Sale Proposal and Charter Amendment Proposal to allow additional time to solicit proxies with respect to these proposals. Approval of the Asset Sale Proposal and the Charter Amendment Proposal are conditions to the consummation of the Merger.
Addressing the Company’s stockholders, Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, noted, “Our ability to complete the Merger, which we believe will maximize value for our stockholders, is contingent upon approval of the Asset Sale Proposal and the Charter Amendment Proposal. Your vote for the Asset Sale Proposal is key to the Merger, and your vote for the Charter Amendment Proposal is important for the operation of the combined company following the Merger.”
The Special Meeting of Stockholders will resume with respect to the Asset Sale Proposal and the Charter Amendment Proposal on Thursday, August 7, 2025 at 11:30 a.m. Eastern Time. The reconvened meeting will be held virtually at www.virtualshareholdermeeting.com/RSLS2025SM. The record date for determining stockholders eligible to vote at the Special Meeting of Stockholders remains the same, June 9, 2025.
ReShape encourages all stockholders of record as of June 9, 2025 that have not yet submitted proxies to submit proxies in favor of the Asset Sale Proposal and the Charter Amendment Proposal and to do so promptly. Those who voted against these proposals are asked to please reconsider their votes based on the factors described in this press release.
The proxy statement for the Special Meeting of Stockholders of ReShape filed on June 24, 2025 contains important information, and this press release should be read in conjunction with the proxy statement, which, along with other relevant materials, is available at no charge at the U.S. Securities and Exchange Commission’s website www.sec.gov and at the Company’s website https://ir.reshapelifesciences.com/financial-information/sec-filings.
YOUR VOTE IS VERY IMPORTANT!
Stockholders can vote by telephone, or via the Internet.
Please follow the easy instructions on the proxy card or voting instruction form previously sent.
For any questions or assistance in voting shares, please call our proxy solicitor,
INNISFREE M&A INCORPORATED
TOLL-FREE, at 1-877-750-8310 (from the U.S. and Canada)
or +1-412-232-3651 (from other countries)
About Vyome
Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome’s immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immune-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. Based in Cambridge, MA, the company has announced its intent to be listed on the Nasdaq exchange under the ticker ‘HIND’ pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) in early 2025. To learn more, please visit www.vyometx.com
About Biorad Medisys
Biorad Medisys Pvt. Ltd.® is a rapidly growing med-tech company dedicated to redefining healthcare standards with precision-engineered medical devices backed by rigorous scientific research. It operates three business units – Indovasive, Orthovasive and Neurovasive. Indovasive offers consumables and equipment in Urology and Gastroenterology. The Orthovasive segment sells a complete range of Knee and Hip implants for both Primary and Revision surgeries. It has recently forayed into Neurovascular BU for selling a wide portfolio of products in peripheral vascular, neurovascular and rehabilitation segments. It has two manufacturing facilities in India and is currently exporting to 50+ countries. To realize its global expansion strategy, it recently acquired a Swiss based company, Marflow, which specializes in commercialization of products in Urology & Gastroenterology.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
Additional Information
In connection with the proposed Merger and sale of assets to Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd. (Asset Sale), ReShape filed with the SEC on June 24, 2025 and mailed or otherwise provided to its stockholders the joint proxy statement/prospectus (joint proxy statement/prospectus) and other relevant documents in connection with the proposed Merger and Asset Sale. Before making a voting decision, ReShape’s stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed Merger and Asset Sale or incorporated by reference therein carefully and in their entirety because they contain important information about ReShape, Vyome and the proposed transactions. Investors and stockholders may obtain a free copy of these materials and other documents filed by ReShape with the SEC at the SEC’s website at www.sec.gov, at ReShape’s website at www.reshapelifesciences.com, or by sending a written request to ReShape at 18 Technology Drive, Suite 110, Irvine, California 92618, Attention: Corporate Secretary.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
FAQ
What proposals did ReShape Lifesciences (RSLS) adjourn at the Special Meeting?
When will RSLS reconvene the Special Meeting for the adjourned proposals?
What is the record date for RSLS stockholders to vote on these proposals?
Why are these RSLS proposals important for stockholders?
How can RSLS stockholders submit their votes for the adjourned proposals?
